First Time Loading...

4D Molecular Therapeutics Inc
NASDAQ:FDMT

Watchlist Manager
4D Molecular Therapeutics Inc Logo
4D Molecular Therapeutics Inc
NASDAQ:FDMT
Watchlist
Price: 25.34 USD -1.17% Market Closed
Updated: May 20, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement
|
Revenue Breakdown

Balance Sheet

629.9m
+85%
Assets
Growth Rates:
1 Year
+158%
3 Years
+133%
5 Years
-
7 Years
-
10 Years
-
29.3m
-9%
Liabilities
Growth Rates:
1 Year
+15%
3 Years
+6%
5 Years
-
7 Years
-
10 Years
-
600.6m
+95%
Equity
Growth Rates:
1 Year
+175%
3 Years
+148%
5 Years
-
7 Years
-
10 Years
-

Balance Sheet Decomposition
4D Molecular Therapeutics Inc

629.9m
Assets
29.3m
Liabilities
629.9m
Assets
29.3m
Liabilities
Current Assets 535.6m
Cash & Short-Term Investments 525.9m
Other Current Assets 9.7m
Non-Current Assets 94.3m
Long-Term Investments 62.9m
PP&E 30.6m
Other Non-Current Assets 771k
Current Liabilities 16.4m
Accounts Payable 4.2m
Accrued Liabilities 10.7m
Other Current Liabilities 1.4m
Non-Current Liabilities 12.9m
Other Non-Current Liabilities 12.9m

Balance Sheet
4D Molecular Therapeutics Inc

Rotate your device to view
Balance Sheet
Currency: USD
Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
24
92
50
277
153
52
249
Cash Equivalents
24
92
50
277
153
52
249
Short-Term Investments
0
0
0
0
95
161
39
Total Receivables
0
1
1
2
0
0
0
Accounts Receivables
0
1
1
2
0
0
0
Other Receivables
0
0
0
0
0
0
0
Other Current Assets
0
1
2
4
9
7
8
Total Current Assets
25
94
53
283
256
221
297
PP&E Net
3
3
5
5
29
35
32
PP&E Gross
3
3
5
5
29
35
32
Accumulated Depreciation
1
2
3
4
5
8
12
Long-Term Investments
0
0
0
0
68
5
11
Other Long-Term Assets
0
0
1
1
1
1
1
Total Assets
27
N/A
97
+255%
58
-40%
288
+395%
354
+23%
262
-26%
340
+30%
Liabilities
Accounts Payable
1
1
2
2
5
3
4
Accrued Liabilities
1
2
3
5
7
10
14
Short-Term Debt
0
0
0
0
0
0
0
Other Current Liabilities
5
6
8
10
4
2
2
Total Current Liabilities
6
8
13
17
16
16
19
Long-Term Debt
0
0
0
0
0
0
0
Other Liabilities
23
14
15
15
18
15
13
Total Liabilities
28
N/A
22
-24%
28
+31%
32
+13%
34
+8%
31
-11%
32
+5%
Equity
Common Stock
19
103
103
0
0
0
0
Retained Earnings
21
30
79
136
207
315
415
Additional Paid In Capital
1
2
6
392
527
547
723
Other Equity
0
0
0
0
0
1
0
Total Equity
1
N/A
75
N/A
30
-60%
256
+755%
319
+24%
231
-28%
308
+33%
Total Liabilities & Equity
27
N/A
97
+255%
58
-40%
288
+395%
354
+23%
262
-26%
340
+30%
Shares Outstanding
Common Shares Outstanding
5
5
5
27
32
33
43

See Also

Summary
FDMT intrinsic value, competitors valuation, and company profile.
DCF Valuation
FDMT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
FDMT stock valuation using valuation multiples.
Wall Street Estimates
FDMT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
FDMT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 139,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.